Cargando…

Suppression of multiple myeloma by mitochondrial targeting

Treatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress. MM cell survival may further be suppressed by limiting cellular cholesterol. Long-chain fatty acid analogs of the MEDICA series promote mitochondrial stres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aisen, Yana, Gatt, Moshe E., Hertz, Rachel, Smeir, Elia, Bar-Tana, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955047/ https://www.ncbi.nlm.nih.gov/pubmed/33712631 http://dx.doi.org/10.1038/s41598-021-83829-2

Ejemplares similares

Suppression of B-Raf(V600E) cancers by MAPK hyper-activation
por: Atiq, Rawan, et al.
Publicado: (2016)

Treatment of ErbB2 breast cancer by mitochondrial targeting
por: Eldad, Sophia, et al.
Publicado: (2020)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression
por: Gilad, Nechama, et al.
Publicado: (2019)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Do older patients truly benefit from advances in myeloma care?
por: Gatt, Moshe E., et al.
Publicado: (2022)

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
por: Gross Even-Zohar, Noa, et al.
Publicado: (2022)

Suppression of FoxO1 Activity by Long-Chain Fatty Acyl Analogs
por: Zatara, Ghadeer, et al.
Publicado: (2011)

PF-4708671 Activates AMPK Independently of p70S6K1 Inhibition
por: Vainer, Gilad W., et al.
Publicado: (2014)

Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma
por: Suzuki, Rikio, et al.
Publicado: (2022)

Prevention of diabetes-promoted colorectal cancer by (n-3) polyunsaturated fatty acids and (n-3) PUFA mimetic
por: Algamas-Dimantov, Anna, et al.
Publicado: (2014)

Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
por: Ortiz-Ruiz, Alejandra, et al.
Publicado: (2021)

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma
por: Kadow, Stephanie, et al.
Publicado: (2022)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Osteoblast suppression in multiple myeloma bone disease
por: Adamik, Juraj, et al.
Publicado: (2018)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
por: Bar-Tana, Jacob
Publicado: (2020)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Targeted therapy of multiple myeloma
por: Zhou, Shan, et al.
Publicado: (2021)

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma
por: Tagde, Ashujit, et al.
Publicado: (2017)

Insulin Resistance, Secretion and Clearance –Taming the Three Effector Encounter of Type 2 Diabetes
por: Bar-Tana, Jacob
Publicado: (2021)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
por: Ruiz-Heredia, Yanira, et al.
Publicado: (2021)

Selinexor: Targeting a novel pathway in multiple myeloma
por: Mo, Clifton C., et al.
Publicado: (2023)

Targeting phosphoglycerate dehydrogenase in multiple myeloma
por: Elsaadi, Samah, et al.
Publicado: (2021)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Targeting the Pim kinases in multiple myeloma
por: Keane, N A, et al.
Publicado: (2015)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Targeting the Microenvironment for Treating Multiple Myeloma
por: Neumeister, Peter, et al.
Publicado: (2022)

Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
por: Liu, Haiyan, et al.
Publicado: (2019)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
por: Zhang, Lu, et al.
Publicado: (2012)

Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ripusi3uq3qup1fosiafhd9c3j